BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  BioSpace Movers & Shakers, Feb. 4

  Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

  February 3, 2022

   · 

  9 min read

   · 

  Alex Keown
• 

  Drug Development

  Future of Key Asset in Question as Gilead Reveals More Holds

  Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.

  February 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  J&J Incurs $610M Charge for Dropped Atopic Dermatitis Program

  J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.

  February 3, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Mersana, Janssen Come Together in Potential $1B ADC Deal

  Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.

  February 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Pfizer Alleges Stolen Trade Secrets at Heart of Regor Therapeutics Launch

  Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.

  February 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact

  The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Early CAR T Patients Still in the Clear 10 Years On

  A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.

  February 3, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  Roche Abandons Crohn’s Program Following Mixed Topline Verdict

  In Roche’s 2021 annual report, the company detailed that group sales rose 9%, pharmaceutical sales up 3%, and diagnostics up a whopping 29%.

  February 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial

  CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Lilly Delays Alzheimer’s Submission in Face of Proposed CMS Limitations

  The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.

  February 3, 2022

   · 

  3 min read

   · 

  Mark Terry